Surrozen Inc./$SRZN
1D1W1MYTD1Y5YMAX
Capital at risk
About Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
- Ticker
- $SRZN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 44
- Headquarters
- South San Francisco, United States
- Website
- www.surrozen.com
Surrozen Inc. Metrics
BasicAdvanced
$194M
-
-$32.19
0.56
-
Price and volume
Market cap
$194M
Beta
0.56
52-week high
$35.00
52-week low
$11.39
Average daily volume
200K
Financial strength
Current ratio
12.141
Quick ratio
11.879
Long term debt to equity
-0.02
Total debt to equity
-0.029
Profitability
EBITDA (TTM)
-44.128
Gross margin (TTM)
-200.38%
Net profit margin (TTM)
-2,885.33%
Operating margin (TTM)
-385.28%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
-25.39%
Return on equity (TTM)
387.21%
Valuation
Price to revenue (TTM)
14.497
Price to book
-0.89
Price to tangible book (TTM)
-0.89
Price to free cash flow (TTM)
-4.77
Free cash flow yield (TTM)
-20.96%
Free cash flow per share (TTM)
-3.47
Growth
Revenue change (TTM)
-8.79%
Earnings per share change (TTM)
519.01%
3-year revenue growth (CAGR)
-2.71%
3-year earnings per share growth (CAGR)
22.34%
Upcoming events
No upcoming events
Surrozen Inc. News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.